Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate
Secondary osteoporosis is defined as a decline in bone mineral density due to any underlying etiology, which usually results in accelerated bone loss than expected for the individual's age or gender. Almost 50-80% of men diagnosed with osteoporosis have secondary osteoporosis. We present a case...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-06, Vol.15 (6), p.e40368 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | e40368 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Batra, Jaskaran Ankireddypalli, Anvitha R Kanugula, Ashok Kumar Gorle, Swathi Kaur, Jasleen |
| description | Secondary osteoporosis is defined as a decline in bone mineral density due to any underlying etiology, which usually results in accelerated bone loss than expected for the individual's age or gender. Almost 50-80% of men diagnosed with osteoporosis have secondary osteoporosis. We present a case of a 60-year-old male with secondary osteoporosis with a history of imatinib mesylate-treated chronic myeloid leukemia (CML). Imatinib mesylate has revolutionized the management of individuals with chronic myeloid leukemia, which is now managed as a chronic disease. Imatinib has been demonstrated to cause dysregulation of bone metabolism. The long-term effects of imatinib on bone metabolism are still unknown. |
| doi_str_mv | 10.7759/cureus.40368 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10263172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2831717016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-fdc150e8c098de048ee7aa6f4c199f4c85c27ccd843fdf98bab02b81fdd196d03</originalsourceid><addsrcrecordid>eNpVkc1LxDAQxYMoKqs3zxLwanXSdJv0JLL4BbvsRRFPIU2mbrTbrEkr7H9vdFX0Mhlefnkz5BFyxOBMiHF1boaAQzwrgJdyi-znrJSZZLLY_tPvkcMYXwCAgchBwC7Z44Ln41LyfdLOY49-5YOPLlLXUU1LyJ5Qh2zeWjrTLdJH1y-Sfuti78Oa-oZOFsF3ztDZGlvvLJ3i8IpLp-l9QN2j3Ty5W-reda6mM4zrNukHZKfRbcTD73NEHq6v7ie32XR-cze5nGaGM-izxho2BpQGKmkRCokotC6bwrCqSlWOTS6MsbLgjW0qWesa8lqyxlpWlRb4iFxsfFdDvURrsOuDbtUquKUOa-W1U_9vOrdQz_5dMchLzkSeHE6-HYJ_GzD26sUPoUtLq1wmgglgZaJON5RJ3xcDNr8jGKjPfNQmH_WVT8KP_671C_-kwT8AY_aOKQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2831717016</pqid></control><display><type>article</type><title>Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Batra, Jaskaran ; Ankireddypalli, Anvitha R ; Kanugula, Ashok Kumar ; Gorle, Swathi ; Kaur, Jasleen</creator><creatorcontrib>Batra, Jaskaran ; Ankireddypalli, Anvitha R ; Kanugula, Ashok Kumar ; Gorle, Swathi ; Kaur, Jasleen</creatorcontrib><description>Secondary osteoporosis is defined as a decline in bone mineral density due to any underlying etiology, which usually results in accelerated bone loss than expected for the individual's age or gender. Almost 50-80% of men diagnosed with osteoporosis have secondary osteoporosis. We present a case of a 60-year-old male with secondary osteoporosis with a history of imatinib mesylate-treated chronic myeloid leukemia (CML). Imatinib mesylate has revolutionized the management of individuals with chronic myeloid leukemia, which is now managed as a chronic disease. Imatinib has been demonstrated to cause dysregulation of bone metabolism. The long-term effects of imatinib on bone metabolism are still unknown.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.40368</identifier><identifier>PMID: 37325683</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Age ; Bone density ; Case reports ; Chronic illnesses ; Endocrinology/Diabetes/Metabolism ; Fractures ; Gender ; Hemoglobin ; Inhibitor drugs ; Kinases ; Laboratories ; Leukemia ; Metabolism ; Oncology ; Osteoporosis ; Patients ; Proteins ; Targeted cancer therapy ; Testosterone ; Women</subject><ispartof>Curēus (Palo Alto, CA), 2023-06, Vol.15 (6), p.e40368</ispartof><rights>Copyright © 2023, Batra et al.</rights><rights>Copyright © 2023, Batra et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Batra et al. 2023 Batra et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-fdc150e8c098de048ee7aa6f4c199f4c85c27ccd843fdf98bab02b81fdd196d03</citedby><cites>FETCH-LOGICAL-c310t-fdc150e8c098de048ee7aa6f4c199f4c85c27ccd843fdf98bab02b81fdd196d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263172/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263172/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37325683$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Batra, Jaskaran</creatorcontrib><creatorcontrib>Ankireddypalli, Anvitha R</creatorcontrib><creatorcontrib>Kanugula, Ashok Kumar</creatorcontrib><creatorcontrib>Gorle, Swathi</creatorcontrib><creatorcontrib>Kaur, Jasleen</creatorcontrib><title>Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Secondary osteoporosis is defined as a decline in bone mineral density due to any underlying etiology, which usually results in accelerated bone loss than expected for the individual's age or gender. Almost 50-80% of men diagnosed with osteoporosis have secondary osteoporosis. We present a case of a 60-year-old male with secondary osteoporosis with a history of imatinib mesylate-treated chronic myeloid leukemia (CML). Imatinib mesylate has revolutionized the management of individuals with chronic myeloid leukemia, which is now managed as a chronic disease. Imatinib has been demonstrated to cause dysregulation of bone metabolism. The long-term effects of imatinib on bone metabolism are still unknown.</description><subject>Age</subject><subject>Bone density</subject><subject>Case reports</subject><subject>Chronic illnesses</subject><subject>Endocrinology/Diabetes/Metabolism</subject><subject>Fractures</subject><subject>Gender</subject><subject>Hemoglobin</subject><subject>Inhibitor drugs</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Metabolism</subject><subject>Oncology</subject><subject>Osteoporosis</subject><subject>Patients</subject><subject>Proteins</subject><subject>Targeted cancer therapy</subject><subject>Testosterone</subject><subject>Women</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkc1LxDAQxYMoKqs3zxLwanXSdJv0JLL4BbvsRRFPIU2mbrTbrEkr7H9vdFX0Mhlefnkz5BFyxOBMiHF1boaAQzwrgJdyi-znrJSZZLLY_tPvkcMYXwCAgchBwC7Z44Ln41LyfdLOY49-5YOPLlLXUU1LyJ5Qh2zeWjrTLdJH1y-Sfuti78Oa-oZOFsF3ztDZGlvvLJ3i8IpLp-l9QN2j3Ty5W-reda6mM4zrNukHZKfRbcTD73NEHq6v7ie32XR-cze5nGaGM-izxho2BpQGKmkRCokotC6bwrCqSlWOTS6MsbLgjW0qWesa8lqyxlpWlRb4iFxsfFdDvURrsOuDbtUquKUOa-W1U_9vOrdQz_5dMchLzkSeHE6-HYJ_GzD26sUPoUtLq1wmgglgZaJON5RJ3xcDNr8jGKjPfNQmH_WVT8KP_671C_-kwT8AY_aOKQ</recordid><startdate>20230613</startdate><enddate>20230613</enddate><creator>Batra, Jaskaran</creator><creator>Ankireddypalli, Anvitha R</creator><creator>Kanugula, Ashok Kumar</creator><creator>Gorle, Swathi</creator><creator>Kaur, Jasleen</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20230613</creationdate><title>Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate</title><author>Batra, Jaskaran ; Ankireddypalli, Anvitha R ; Kanugula, Ashok Kumar ; Gorle, Swathi ; Kaur, Jasleen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-fdc150e8c098de048ee7aa6f4c199f4c85c27ccd843fdf98bab02b81fdd196d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Bone density</topic><topic>Case reports</topic><topic>Chronic illnesses</topic><topic>Endocrinology/Diabetes/Metabolism</topic><topic>Fractures</topic><topic>Gender</topic><topic>Hemoglobin</topic><topic>Inhibitor drugs</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Metabolism</topic><topic>Oncology</topic><topic>Osteoporosis</topic><topic>Patients</topic><topic>Proteins</topic><topic>Targeted cancer therapy</topic><topic>Testosterone</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Batra, Jaskaran</creatorcontrib><creatorcontrib>Ankireddypalli, Anvitha R</creatorcontrib><creatorcontrib>Kanugula, Ashok Kumar</creatorcontrib><creatorcontrib>Gorle, Swathi</creatorcontrib><creatorcontrib>Kaur, Jasleen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Batra, Jaskaran</au><au>Ankireddypalli, Anvitha R</au><au>Kanugula, Ashok Kumar</au><au>Gorle, Swathi</au><au>Kaur, Jasleen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-06-13</date><risdate>2023</risdate><volume>15</volume><issue>6</issue><spage>e40368</spage><pages>e40368-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Secondary osteoporosis is defined as a decline in bone mineral density due to any underlying etiology, which usually results in accelerated bone loss than expected for the individual's age or gender. Almost 50-80% of men diagnosed with osteoporosis have secondary osteoporosis. We present a case of a 60-year-old male with secondary osteoporosis with a history of imatinib mesylate-treated chronic myeloid leukemia (CML). Imatinib mesylate has revolutionized the management of individuals with chronic myeloid leukemia, which is now managed as a chronic disease. Imatinib has been demonstrated to cause dysregulation of bone metabolism. The long-term effects of imatinib on bone metabolism are still unknown.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>37325683</pmid><doi>10.7759/cureus.40368</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-06, Vol.15 (6), p.e40368 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10263172 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Age Bone density Case reports Chronic illnesses Endocrinology/Diabetes/Metabolism Fractures Gender Hemoglobin Inhibitor drugs Kinases Laboratories Leukemia Metabolism Oncology Osteoporosis Patients Proteins Targeted cancer therapy Testosterone Women |
| title | Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T05%3A20%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteoporosis%20in%20a%2060-Year-Old%20Male%20With%20a%20History%20of%20Chronic%20Myeloid%20Leukemia%20Treated%20With%20Imatinib%20Mesylate&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Batra,%20Jaskaran&rft.date=2023-06-13&rft.volume=15&rft.issue=6&rft.spage=e40368&rft.pages=e40368-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.40368&rft_dat=%3Cproquest_pubme%3E2831717016%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2831717016&rft_id=info:pmid/37325683&rfr_iscdi=true |